Piper Sandler Maintains Neutral on Myriad Genetics, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst John Peterson maintains a Neutral rating on Myriad Genetics (NASDAQ:MYGN) and raises the price target from $28 to $30.

August 13, 2024 | 11:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has maintained a Neutral rating on Myriad Genetics and raised the price target from $28 to $30.
The raised price target from $28 to $30 suggests a positive outlook on Myriad Genetics' future performance, which could lead to a short-term increase in stock price. However, the Neutral rating indicates that the analyst does not see significant upside potential, balancing the impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100